The combination of rising drug costs in the US and increasing financial stress for individual patients has triggered intense national concern. One target has come under particular scrutiny: rebates. A new report published by ICER and the OHE describes how alternatives to the current rebate system offer potential disadvantages as well as potential benefits. It outlines evidence presented to date and key questions that still need to be answered.
Making Outcome-based payments a reality in the NHS authored by The Office of Health Economics, RAND Europe, King’s College London, and Cancer Research UK, and commissioned by Cancer Research UK in partnership with Greater Manchester Health & Social Care Partnership, explores alternative pricing models and the implications of outcome-based payment schemes for improving access to cost-effective cancer drugs.
The fourth annual meeting of the HTAi Asia Policy Forum was held in November 2016. OHE produced Background Briefing Papers for each of these four meetings covering a variety of topics relevant to the development of HTA in Asia, all of which are now available. This post contains a summary of each report.
OHE has just published two new briefings entitled ‘New Age Decision Making in HTA’ and ‘How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?’. Both publications are reports of panel sessions held at the HTAi 2016 meeting in Tokyo.
The Spanish Health Economics Association (AES) Conference was held at the University of Murcia, 15-18th June 2016. The topic of the meeting was “Reforms under the microscope”. Several members of the OHE team attended and contributed to the conference; this post summarises their activity.
The blog provides links to slide sets for presentations relating to going ‘beyond QALYs’ when valuing health care interventions, managed entry agreements within the UK pharmaceutical landscape, new business models for antibiotics, and economics of the market for medicines